Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARA 290 for diabetic macular oedema
ISRCTN16962255Phase 2Completed
- Sponsor
- Belfast Health and Social Care Trust
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 2, open-label, single-arm trial of cibinetide in diabetic macular edema (DME), sponsored by Belfast Health and Social Care Trust. Primary endpoint: Best corrected distance visual acuity. Started Sep 2015; status: completed.
02
Drugs
cibinetide
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ISRCTN16962255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16962255.